Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer
Manuela Santarosa(Centro di Riferimento Oncologico), Mauro Boiocchi(Centro di Riferimento Oncologico), Riccardo Dolcetti(Translational Research Institute), Diana Crivellari(Centro di Riferimento Oncologico), Angelo Gallo(Centro di Riferimento Oncologico), Maria Antonietta Pizzichetta(University of Trieste), Salvatore Tumolo, Maria Grazia Tibiletti(University of Insubria), Laura Del Tin(Centro di Riferimento Oncologico), Alessandra Viel(Centro di Riferimento Oncologico), Maria Donatella Magri(Centro di Riferimento Oncologico)
International Journal of Cancer
November 23, 1998
Cited by 3
Related Papers
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
Dermoscopic Evaluation of Amelanotic and Hypomelanotic Melanoma
|Archives of Dermatology|2008|304
Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII
|Journal of Clinical Oncology|2000|295
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
|The Lancet|2000|286
Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
|JNCI Journal of the National Cancer Institute|2007|242